Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cefpodoxime + ofloxacin is a fixed-dose combination antibiotic consisting of cefpodoxime proxetil, a third-generation cephalosporin, and ofloxacin, a second-generation fluoroquinolone. Cefpodoxime works by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs), while ofloxacin inhibits bacterial DNA replication by targeting DNA gyrase and topoisomerase IV. This combination is typically used for the treatment of various bacterial infections, including respiratory tract infections, urinary tract infections, and typhoid fever, particularly where dual coverage or synergistic effects against Gram-positive and Gram-negative pathogens are desired. It is developed and marketed by companies like Cosmas Pharmaceuticals in oral formulations such as tablets and dry syrups.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cefpodoxime + ofloxacin.